Medinet Co Ltd
TSE:2370
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Medinet Co Ltd
Other Equity
Medinet Co Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medinet Co Ltd
TSE:2370
|
Other Equity
¥2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Carna Biosciences Inc
TSE:4572
|
Other Equity
¥81.4m
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
43%
|
|
|
S
|
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
|
Other Equity
-¥258.5m
|
CAGR 3-Years
45%
|
CAGR 5-Years
36%
|
CAGR 10-Years
18%
|
|
|
CellSource Co Ltd
TSE:4880
|
Other Equity
¥1k
|
CAGR 3-Years
-21%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
Other Equity
-¥1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DNA Chip Research Inc
TSE:2397
|
Other Equity
¥1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Medinet Co Ltd
Glance View
MEDINET Co., Ltd. engages in cell processing business. The company is headquartered in Ota-Ku, Tokyo-To and currently employs 83 full-time employees. The company went IPO on 2003-10-08. The company operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. The company also provides comprehensive support services for immune cell therapy.
See Also
What is Medinet Co Ltd's Other Equity?
Other Equity
2k
JPY
Based on the financial report for Dec 31, 2025, Medinet Co Ltd's Other Equity amounts to 2k JPY.
